TuHURA Biosciences (HURA) Competitors

TuHURA Biosciences logo
$1.40 +0.00 (+0.21%)
As of 01:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

HURA vs. EDIT, SRZN, ALT, AVTX, and SVA

Should you buy TuHURA Biosciences stock or one of its competitors? TuHURA Biosciences's main competitors and comparable companies include Editas Medicine (EDIT), Surrozen (SRZN), Altimmune (ALT), Avalo Therapeutics (AVTX), and Sinovac Biotech (SVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TuHURA Biosciences compare to Editas Medicine?

TuHURA Biosciences (NASDAQ:HURA) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Editas Medicine had 7 more articles in the media than TuHURA Biosciences. MarketBeat recorded 11 mentions for Editas Medicine and 4 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.96 beat Editas Medicine's score of 0.34 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TuHURA Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Editas Medicine
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

TuHURA Biosciences has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TuHURA BiosciencesN/AN/A-$30.05M-$0.50N/A
Editas Medicine$40.52M6.97-$160.06M-$0.62N/A

TuHURA Biosciences currently has a consensus target price of $9.50, suggesting a potential upside of 578.57%. Editas Medicine has a consensus target price of $5.83, suggesting a potential upside of 218.76%. Given TuHURA Biosciences' higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than Editas Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Editas Medicine
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

TuHURA Biosciences has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

TuHURA Biosciences has a net margin of 0.00% compared to Editas Medicine's net margin of -144.95%. Editas Medicine's return on equity of -130.43% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TuHURA BiosciencesN/A -148.80% -95.74%
Editas Medicine -144.95%-130.43%-36.45%

Summary

Editas Medicine beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Surrozen?

Surrozen (NASDAQ:SRZN) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Surrozen presently has a consensus price target of $61.75, indicating a potential upside of 105.97%. TuHURA Biosciences has a consensus price target of $9.50, indicating a potential upside of 578.57%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Surrozen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 6.1% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TuHURA Biosciences has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Surrozen-2,885.33% N/A -112.96%
TuHURA Biosciences N/A -148.80%-95.74%

In the previous week, Surrozen had 10 more articles in the media than TuHURA Biosciences. MarketBeat recorded 14 mentions for Surrozen and 4 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.96 beat Surrozen's score of 0.07 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Surrozen
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
TuHURA Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

TuHURA Biosciences has lower revenue, but higher earnings than Surrozen. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surrozen$3.48M164.20-$242.03M-$43.21N/A
TuHURA BiosciencesN/AN/A-$30.05M-$0.50N/A

Summary

Surrozen and TuHURA Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Altimmune?

TuHURA Biosciences (NASDAQ:HURA) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TuHURA Biosciences presently has a consensus price target of $9.50, suggesting a potential upside of 578.57%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 836.82%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than TuHURA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Altimmune
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

In the previous week, Altimmune had 21 more articles in the media than TuHURA Biosciences. MarketBeat recorded 25 mentions for Altimmune and 4 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.96 beat Altimmune's score of 0.50 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TuHURA Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Altimmune
7 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

TuHURA Biosciences has higher earnings, but lower revenue than Altimmune. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TuHURA BiosciencesN/AN/A-$30.05M-$0.50N/A
Altimmune$40K7,443.07-$88.09M-$0.72N/A

TuHURA Biosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

Altimmune's return on equity of -29.26% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TuHURA BiosciencesN/A -148.80% -95.74%
Altimmune N/A -29.26%-25.48%

Summary

Altimmune beats TuHURA Biosciences on 10 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, TuHURA Biosciences had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for TuHURA Biosciences and 3 mentions for Avalo Therapeutics. TuHURA Biosciences' average media sentiment score of 0.96 beat Avalo Therapeutics' score of 0.91 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avalo Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TuHURA Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Avalo Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

Avalo Therapeutics currently has a consensus price target of $36.82, indicating a potential upside of 416.38%. TuHURA Biosciences has a consensus price target of $9.50, indicating a potential upside of 578.57%. Given TuHURA Biosciences' higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Avalo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

TuHURA Biosciences has lower revenue, but higher earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalo Therapeutics$60K6,870.94-$78.26M-$2.52N/A
TuHURA BiosciencesN/AN/A-$30.05M-$0.50N/A

Avalo Therapeutics' return on equity of -34.21% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Avalo TherapeuticsN/A -34.21% -29.84%
TuHURA Biosciences N/A -148.80%-95.74%

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Avalo Therapeutics beats TuHURA Biosciences on 7 of the 13 factors compared between the two stocks.

How does TuHURA Biosciences compare to Sinovac Biotech?

TuHURA Biosciences (NASDAQ:HURA) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, TuHURA Biosciences had 4 more articles in the media than Sinovac Biotech. MarketBeat recorded 4 mentions for TuHURA Biosciences and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 1.79 beat TuHURA Biosciences' score of 0.96 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
TuHURA Biosciences Positive
Sinovac Biotech Very Positive

Sinovac Biotech's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TuHURA BiosciencesN/A -148.80% -95.74%
Sinovac Biotech N/A N/A N/A

TuHURA Biosciences has higher earnings, but lower revenue than Sinovac Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TuHURA BiosciencesN/AN/A-$30.05M-$0.50N/A
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A

TuHURA Biosciences currently has a consensus price target of $9.50, suggesting a potential upside of 578.57%. Sinovac Biotech has a consensus price target of $1.00, suggesting a potential downside of 84.54%. Given TuHURA Biosciences' higher probable upside, equities research analysts plainly believe TuHURA Biosciences is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

0.6% of TuHURA Biosciences shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TuHURA Biosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

Sinovac Biotech beats TuHURA Biosciences on 7 of the 12 factors compared between the two stocks.

Get TuHURA Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HURA vs. The Competition

MetricTuHURA BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$92.06M$4.00B$7.66B$11.73B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio-2.8024.7134.0030.04
Price / SalesN/A15.848.445.70
Price / CashN/A22.9521.0121.90
Price / Book5.014.194.483.75
Net Income-$30.05M-$24.10M$3.51B$394.12M
7 Day Performance-7.70%-7.66%-5.93%-5.63%
1 Month Performance-20.28%-5.73%-4.31%-6.93%
1 Year Performance-27.31%-6.16%-1.15%-7.12%

TuHURA Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HURA
TuHURA Biosciences
1.8761 of 5 stars
$1.40
+0.2%
$9.50
+577.1%
-25.5%$92.06MN/AN/A22
EDIT
Editas Medicine
2.1453 of 5 stars
$2.52
-8.5%
$5.83
+131.9%
-29.1%$386.25M$40.52MN/A87
SRZN
Surrozen
2.6427 of 5 stars
$32.69
+2.1%
$55.67
+70.3%
+134.2%$382.64M$3.48MN/A44
ALT
Altimmune
3.9453 of 5 stars
$1.94
-8.7%
$14.33
+640.7%
-63.5%$376.40M$40KN/A57
AVTX
Avalo Therapeutics
4.2007 of 5 stars
$6.98
-4.0%
$36.82
+427.4%
-57.8%$374.87M$60KN/A33

Related Companies and Tools


This page (NASDAQ:HURA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners